An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia - Wikidata - wikimedia - TriplyDB

An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia

An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia

http://www.wikidata.org/entity/Q28474978

about

Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaedit Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data Designing the next generation of medicines for malaria control and eradication Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study.A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.Malaria: an update on current chemotherapy.A small amount of fat does not affect piperaquine exposure in patients with malaria.Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India.The global pipeline of new medicines for the control and elimination of malaria Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in southern Laos A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa MMV in partnership: the Eurartesim® experience.Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers.Malaria evolution in South Asia: knowledge for control and elimination.Antimalarial drug policy in India: past, present & future.Therapy of vector-borne protozoan infections in nonendemic settings.Efficacy and safety of artesunate-mefloquine therapy for treating uncomplicated Plasmodium falciparum malaria: systematic review and meta-analysis.Dihydroartemisinin-piperaquine versus artesunate-amodiaquine for treatment of malaria infection in pregnancy in Ghana: an open-label, randomised, non-inferiority trial.Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua kouté, Côte d'Ivoire.Maximising the public health benefit of antimalarials.Antimalarial activity of Malaria Box Compounds against Plasmodium falciparum clinical isolates.Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Africa Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

P2860

Q21032449-EE38B757-FEF0-4AAC-8849-1C86228B4C8B Q24201077-8359A60E-2661-4118-8420-32D89F14A6C5 Q26822489-5E902B4C-B37C-4BD2-B020-3C56997007BD Q26859195-BA7FC420-EDF1-4908-9185-4FF18C7E916C Q26866187-78B234F5-8332-4870-9437-4AC1BC485938 Q28071256-197485D2-79CD-4B8C-9C53-BFCF1E1E83CA Q28477853-1A167F53-7074-411D-9D5F-6E1E50374204 Q28552793-65C823AB-97CA-40AE-B1C6-C5E49476003B Q33678483-A813117E-38F8-48B0-B7E8-D211F5713715 Q34298973-8B5C6783-FC22-4F71-A5E7-2E22E3E369FB Q34299178-0F153D87-38AD-4EB9-B0FD-16C7DDBC50FD Q34329292-1860556C-4872-4E27-97CB-EB3874432045 Q34341784-056919A9-162E-48EA-8653-D4EC10901279 Q34433106-01B01CA2-3BFF-4B79-8DAE-EA6CA86A6346 Q35191426-9608E8CF-0EA9-4D1E-BC16-9702C3E11A48 Q35519260-55696BE4-0760-4F16-9DE9-4FDD8CBCD2DD Q35820930-86AC5456-96B0-45C0-9156-F3A486FF1D19 Q35834198-BBD5B535-B514-45C2-854D-063FDD7FF7A2 Q36080127-977F0FA6-CA49-4195-A1D2-816ABD23B10D Q36138872-1B97B5FB-07B8-4F03-BABD-EBD3FDA2EE5E Q36179156-C6111AA8-1993-45B6-A6CF-E9E9053DCD33 Q36320249-4601A9ED-BA40-41EC-A0D0-DC6E8EA6ED12 Q36471679-569B276C-F23D-405E-9E09-AFB510B072BB Q36715829-2837BD34-920A-4E16-8ECB-0BECDEB2B565 Q36952896-6F1B94A3-88B1-41FE-96FD-C4A6AEA4CEB1 Q37263344-DDC63A8F-0474-4BC0-B143-11E374B9171B Q37488243-235CCE0F-6658-4B01-8788-F58B38624812 Q37726201-E072F193-13EE-41D1-8517-A5A8AEEA1D60 Q37879203-ADA0618C-1956-4CCA-ABDC-B9E952524677 Q39063353-0DDDEAFE-14AD-4D6B-90A7-D812F444B9C5 Q39327919-FF113641-4D68-4198-950F-71353D52E0CD Q40338028-095F68DC-AFA6-4F0A-8760-0DAA88401F95 Q42910618-77A961A4-C144-4427-A6B4-1B7EDE7C6972 Q43434845-FAE97D64-E9A0-47C9-8BEF-14B37E9D4EC1 Q43923958-B7F9D71A-3383-48C8-8E1D-80FADC961004 Q52615236-2C3FF304-DD1E-4DE9-811C-1E56BF2B894B

P2860

An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia

http://www.wikidata.org/entity/Q28474978

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

An open-label, randomised stud ...... for falciparum malaria in Asia

@ast

An open-label, randomised stud ...... for falciparum malaria in Asia

@en

An open-label, randomised stud ...... for falciparum malaria in Asia

@nl

type

label

An open-label, randomised stud ...... for falciparum malaria in Asia

@ast

An open-label, randomised stud ...... for falciparum malaria in Asia

@en

An open-label, randomised stud ...... for falciparum malaria in Asia

@nl

prefLabel

An open-label, randomised stud ...... for falciparum malaria in Asia

@ast

An open-label, randomised stud ...... for falciparum malaria in Asia

@en

An open-label, randomised stud ...... for falciparum malaria in Asia

@nl

P1433

Q28474978-4A73C9BC-7771-415F-9F93-F38EAA20F0D4

P1476

Q28474978-906AB0B9-D4BE-4F5A-A4C4-24981A401A3B

P2093

Q28474978-0FE33B1F-9354-4326-96B9-42084CDC0DF9

Q28474978-3A3D4132-E52B-4BBC-AC35-F58C5C04281D

Q28474978-3A977DDE-D986-421A-BF54-280C89E9B54D

Q28474978-3BC82A35-219B-4267-BB0B-B5FA8610DAC1

Q28474978-4691D15B-839B-47F7-8BA8-6B6C150B6DA3

Q28474978-59011818-C3B8-4059-8FC8-399A87F05482

Q28474978-59819509-9FDF-42E7-8D40-453E9B747FBE

Q28474978-7610D4E7-4234-48FD-8B47-ECC135D6754F

Q28474978-803F5ED4-B1D5-4FBB-98A0-504B7232668F

Q28474978-B1DB5432-B703-4E1E-BF18-8622C8B4282F

P2860

Q28474978-014C27D8-2FB9-4A7D-96DC-427F7292808B

Q28474978-0A34611E-D2B0-4490-9751-973023099AEA

Q28474978-0A623500-7111-49E2-88B8-A1FEC044A36B

Q28474978-0F9C2DFD-ADF0-4044-B453-36661737413B

Q28474978-10FF3CA4-E1BE-4B5C-9A5A-0F7C653E5E52

Q28474978-13DF616A-77B3-4CFD-9C94-81088F82C942

Q28474978-21ACC8FE-6508-40F9-BAF1-29006DA3BB7D

Q28474978-23CF8C56-DBE4-4E43-81F0-B643567C1946

Q28474978-41C3A68C-0AEE-4F92-AA97-A108F80D6C80

Q28474978-4683E411-79FA-47ED-B574-374C429E3851

P304

Q28474978-E5A4B55B-A15E-489C-9ABB-1CACD7EC4054

P31

Q28474978-285A4636-2821-43AB-8005-AB708151FE62

P3181

Q28474978-17D857FF-2810-4866-8409-24F42E2366B4

P356

Q28474978-F568335F-8A52-4015-A944-B4851C90D40F

P407

Q28474978-345680BC-0CAF-410A-9163-0D07FC7EE764

P433

Q28474978-A0197D60-1708-460B-B239-F89414EEB19D

P478

Q28474978-F173D7DC-42CA-4DD5-9752-5120FAF2537B

P50

Q28474978-2AD17A28-D691-4620-9613-E0EA6EB06B3E

Q28474978-2F32B590-E762-4BEB-B2BF-C0C27D70836F

Q28474978-55406411-BF05-436D-8905-F7585915350D

Q28474978-6DF881E2-33AA-40B4-B1FC-6B3E80282042

Q28474978-767E4531-16BB-4F65-89D4-60D966D4A62C

Q28474978-BDBEC07D-63A8-4678-B561-C38AC75CC656

Q28474978-F1EE703E-6276-4395-B9A0-BDC0D0ECA414

P577

Q28474978-2775D72D-BE18-45B8-B620-E99D65D5024F

P5875

Q28474978-52C095D2-65F1-493C-81F7-04358825C062

P698

Q28474978-3FA73D00-8495-4A21-8931-DDE5311F93E2

P921

Q28474978-3373BF1B-0F1F-47F2-9057-B995F847BA47

Q28474978-6DB10794-496F-43E1-8580-C5501219DF4F

Q28474978-81EDD34B-5A50-4738-83EF-B7C15ABB973D

P932

Q28474978-1A112E9D-9A82-45C5-8B8A-7CB377A8143B

P3181

P356

JOURNAL.PONE.0011880

P1433

P1476

An open-label, randomised stud ...... for falciparum malaria in Asia

@en

P2093

Antonella Bacchieri

http://www.w3.org/2001/XMLSchema#string

Ashwani Kumar

http://www.w3.org/2001/XMLSchema#string

Bappanad H K Rao

http://www.w3.org/2001/XMLSchema#string

Chirapong Uthaisil

http://www.w3.org/2001/XMLSchema#string

David Ubben

http://www.w3.org/2001/XMLSchema#string

Marco Corsi

http://www.w3.org/2001/XMLSchema#string

Nagesh Dubhashi

http://www.w3.org/2001/XMLSchema#string

Paul N Newton

http://www.w3.org/2001/XMLSchema#string

Prabash C Bhattacharya

http://www.w3.org/2001/XMLSchema#string

Ronnatrai Ruangveerayuth

http://www.w3.org/2001/XMLSchema#string

P2860

Qinghaosu (Artemisinin): The Price of Success

Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border

Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment

Artemisinin Resistance in Plasmodium falciparum Malaria

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003.

A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand.

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.

Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.

P304

e11880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2887362

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0011880

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Sasithon Pukrittayakamee

Maniphone Khanthavong

Tiengkham Pongvongsa

Srivicha Krudsood

P577

2010-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45508963

http://www.w3.org/2001/XMLSchema#string

P698

20689583

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

2912766

http://www.w3.org/2001/XMLSchema#string